EP
IRWD icon

Essential Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Essential Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.2K Sell
6,232
-15,870
-72% -$61.2K 0.01% 805
2026
Q1 		$77.6K Buy
22,102
+21
+0.1% +$86 0.03% 482
2025
Q4 		$74.4K Buy
22,081
+153
+0.7% +$397 0.02% 517
2025
Q3 		$28.7K Buy
21,928
+7,469
+52% +$7.73K 0.01% 773
2025
Q2 		$10.4K Buy
+14,459
New +$11.4K ﹤0.01% 832

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Essential Partners's IRWD Position: Q2 2026 in Review

Essential Partners reduced its Ironwood Pharmaceuticals (IRWD) stake by 72% in Q2 2026, selling an estimated $61.2K and leaving 6,232 shares worth $26.2K. The position accounts for 0.01% of the portfolio, ranked #805.

Essential Partners first reported a position in IRWD in Q2 2025 and has held it in 5 quarters since. The position peaked at $77.6K in Q1 2026. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Essential Partners held 6,232 shares of Ironwood Pharmaceuticals worth $26.2K as of Q2 2026.
  • Essential Partners sold 15,870 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $61.2K.
  • Ironwood Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q2 2026, its #805 holding.
  • Essential Partners first reported a position in Ironwood Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Ironwood Pharmaceuticals position peaked at $77.6K in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.